Kyusik Kim
About Kyusik Kim
Kyusik Kim is a Scientist II at Tessera Therapeutics, specializing in virology and immunology. He has a Ph.D. from the University of Massachusetts Medical School and has contributed to multiple publications in the field of viral infections.
Work at Tessera Therapeutics
Kyusik Kim has been employed at Tessera Therapeutics as a Scientist II since 2022. In this role, he contributes to research and development efforts in Somerville, Massachusetts. Prior to this position, he worked as a Scientist I at the same organization from 2020 to 2022. His work primarily focuses on advancing therapeutic technologies and methodologies.
Education and Expertise
Kyusik Kim earned his Doctor of Philosophy (PhD) in Virology and Immunology from the University of Massachusetts Medical School, where he studied from 2014 to 2020. He also holds a Bachelor of Science in Engineering (B.S.E) in Biotechnology and Bioengineering from Yonsei University, where he studied from 2006 to 2013. His educational background provides a strong foundation in viral infections and immune responses.
Background
Kyusik Kim's research experience includes a significant tenure as a Ph.D. student at the University of Massachusetts Medical School and a research internship at Institut Pasteur Korea in 2013. He also served as an Undergraduate Research Assistant at Yonsei University from 2010 to 2011. This diverse background has equipped him with a comprehensive understanding of virology and immunology.
Research Contributions
Kyusik Kim has contributed to eight publications focusing on immune responses to viral infections and host-virus interactions. His research includes the development of lentiviral vectors optimized for higher transduction of primary human cells, showcasing his expertise in viral vector design and application.
Technical Skills
Kyusik Kim possesses extensive skills in generating and handling infectious viruses, particularly HIV-1, in a BSL2+ laboratory environment. He has significant experience in genome editing using CRISPR/Cas9 technology and is proficient in culturing primary human immune cells, including macrophages, dendritic cells, CD4+ T cells, and CD34+ hematopoietic stem cells.